Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of March 2026, specifically detailing share repurchases executed on March 12, 2026. The shares were purchased through BNP Paribas SA under a non-discretionary agreement announced on February 17, 2026, as part of GSK's existing buyback programme.
Key Financial Metrics and Transaction Details
The filing details a single day of significant share repurchase activity. The following metrics summarize the transaction:
- Date of Purchase: March 12, 2026
- Aggregate Shares Purchased: 790,000 ordinary shares
- Price Range: Lowest price paid was 2,016.00 GBp; Highest price paid was 2,057.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,036.73 GBp
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Share Holdings: Following this purchase, GSK holds 249,371,503 ordinary shares in treasury.
- Shares in Issue: 4,066,797,319 ordinary shares (excluding treasury shares).
- Treasury Voting Rights: Treasury shares represent 6.13% of total voting rights.
Material Changes and Programme Progress
Since the commencement of the current non-discretionary agreement on February 17, 2026, GSK has purchased a total of 9,480,409 ordinary shares. The March 12 transaction represents a continuation of this programme. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a transaction-specific report rather than a financial results announcement.
Outlook and Management Commentary
The filing confirms the ongoing execution of the share buyback programme. No new guidance, outlook, or specific management commentary regarding future financial performance or strategic shifts is provided in this document. The company includes a standard cautionary statement regarding forward-looking statements, directing investors to the "Risk Factors" section of the 2025 Annual Report on Form 20-F.
Risks and Contingencies
The filing references standard risks associated with forward-looking statements but does not disclose any new material risks, contingencies, or unusual items specific to this transaction.
Key Facts for Investor Verification
- Verify the total number of shares purchased under the current buyback programme (9,480,409 since Feb 17, 2026) against the company's total authorized buyback limit.
- Confirm the current percentage of voting rights held in treasury (6.13%) to assess potential dilution or concentration of voting power.
- Review the 2025 Annual Report on Form 20-F for the full list of risk factors referenced in the cautionary statement.
- Monitor subsequent filings to track the remaining capacity and execution pace of the buyback programme.